Otherwise, this looks like a fantastic growth stock that just doubled its addressable market with the Zava acquisition. Today ...

By Amina Niasse (Reuters) -Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up ...

Hims & Hers Health has seen massive success, aided by the growing use of GLP-1 drugs. Click here to find out why I downgrade ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Hims & Hers (NYSE: HIMS) stock, a prominent player in the booming telehealth sector, has undeniably captured significant investor attention recently. Perhaps you, like many others, have been caught up ...

Hims & Hers leverages ZAVA's expertise to enter Europe's weight-loss market, boosting growth and profitability. Read what ...

Hims & Hers stock is on the upswing after the company secured a weight-loss drug partnership. Hims & Hers is acquiring its way into Europe and wants to build more personalized drugs for its ...

Per the chart above, roughly 35% of Hims & Hers float is sold short. Investors who short a stock are betting its price will fall. Short interest of 10% or more is considered unusually high. Not only ...

Hims & Hers expanding in Europe with the purchase of London-based digital health platform ZAVA. The acquisition gives the ...

Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look ...

Hims & Hers is the newest darling disrupting the telemedicine space. While shares have jumped 157% over the last year, Wall Street analysts don't seem overly bullish on the stock. Despite ...

The E.U.'s universal healthcare policies make pharmaceuticals much more affordable relative to the U.S., meaning there could ...